Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lyme Disease Overview 6
Therapeutics Development 7
Pipeline Products for Lyme Disease-Overview 7
Pipeline Products for Lyme Disease-Comparative Analysis 8
Lyme Disease-Therapeutics under Development by Companies 9
Lyme Disease-Therapeutics under Investigation by Universities/Institutes 10
Lyme Disease-Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Lyme Disease-Products under Development by Companies 14
Lyme Disease-Products under Investigation by Universities/Institutes 15
Lyme Disease-Companies Involved in Therapeutics Development 16
Baxter International Inc. 16
LondonPharma Ltd 17
Valneva SE 18
VG Life Sciences, Inc. 19
Lyme Disease-Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
azithromycin gel-Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
lyme borreliosis vaccine-Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
lyme disease vaccine-Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
lyme disease vaccine 2-Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule for Lyme Disease-Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
VGV-L-Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VLA-15-Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Lyme Disease-Recent Pipeline Updates 35
Lyme Disease-Dormant Projects 37
Lyme Disease-Product Development Milestones 39
Featured News & Press Releases 39
Mar 07, 2012: Viral Genetics Submits Pre-IND Document For Lyme Disease Drug Candidate To FDA 39
Oct 21, 2008: Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study and Team Receives Positive Feedback at ILADS Conference, Study Model Potentially Applies to HIV/AIDS and Other Immune Based Diseases. 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
